Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin system in early postmenopausal women.
We investigated the serum levels of both receptor activator of nuclear factor kappaB ligand (RANKL) and its decoy receptor osteoprotegerin (OPG) in postmenopausal healthy women after a 1-yr therapy with genistein, (n = 30; 54 mg/d), hormone replacement therapy (n = 30; 1 mg/d 17beta-estradiol combined with norethisterone acetate) and placebo (n = 30). By comparison with placebo, the soluble RANKL (sRANKL)/OPG ratio was lower in the genistein group (-69 +/- 7%; P < 0.01 vs. placebo 81 +/- 24%) and in hormone replacement therapy-treated women (-11 +/- 2%; P < 0.01 vs. placebo). A positive correlation (r = 0.63; P < 0.01) was found between 1-yr percentage change in sRANKL/OPG ratio and 1-yr change in urinary deoxypyridinoline, a bone resorption marker. A negative correlation was observed between 1-yr percentage change in sRANKL/OPG ratio and 1-yr change in femoral neck bone mineral density (r = -0.7; P < 0.01). Our findings suggest that the sRANKL-OPG system may mediate the beneficial effects of genistein on bone remodeling in postmenopausal women.
Crisafulli
Alessandra
A
Department of Biomedical Sciences, Section of Pharmacology, University of Modena and Reggio Emilia, 41100 Modena, Italy.
Altavilla
Domenica
D
Squadrito
Giovanni
G
Romeo
Adolfo
A
Adamo
Elena B
EB
Marini
Rolando
R
Inferrera
Maria A
MA
Marini
Herbert
H
Bitto
Alessandra
A
D'Anna
Rosario
R
Corrado
Francesco
F
Bartolone
Sebastiano
S
Frisina
Nicola
N
Squadrito
Francesco
F
D000596:Amino Acids / Q000652:urine; D015519:Bone Density; D016723:Bone Remodeling; D001862:Bone Resorption; D002352:Carrier Proteins / Q000097:blood*; D004311:Double-Blind Method; D004958:Estradiol / Q000008:administration & dosage; D015914:Estrogen Replacement Therapy; D005260:Female; D005272:Femur Neck; D019833:Genistein / Q000008:administration & dosage*; D006023:Glycoproteins / Q000097:blood*; D006801:Humans; D008562:Membrane Glycoproteins / Q000097:blood*; D008875:Middle Aged; D009640:Norethindrone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077563:Norethindrone Acetate; D053244:Osteoprotegerin; D010919:Placebos; D017698:Postmenopause; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D018160:Receptors, Cytoplasmic and Nuclear / Q000097:blood*; D018124:Receptors, Tumor Necrosis Factor
D000596:Amino Acids; D002352:Carrier Proteins; D006023:Glycoproteins; D008562:Membrane Glycoproteins; D053244:Osteoprotegerin; D010919:Placebos; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; C505686:TNFRSF11A protein, human; C506030:TNFRSF11B protein, human; C505688:TNFSF11 protein, human; D004958:Estradiol; C036020:deoxypyridinoline; D000077563:Norethindrone Acetate; D019833:Genistein; D009640:Norethindrone